AgingResearch.NewsJoin free

AAV-TK2

AAV-TK2 has been studied in 1 paper since 2021: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Aug 13, 2021: “Synergistic Deoxynucleoside and Gene Therapies for Thymidine Kinase 2 Deficiency”.

Intervention

1 paper studies it2 findingsUpdated

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funders: Eunice Kennedy Shriver National Institute of Child Health and Human Development and 3 more
  • Animals1

What did studies of AAV-TK2 find?

2

Studies of AAV-TK2 measured 2 outcomes; the most studied are disease onset (1 study) and lifespan (1).

Disease onset

downin mice1

1 study

  1. AAV-TK2 decreases disease onset in mice.

    “delayed disease onset, and increased lifespan.”

    Animalsin Tk2KI mice

    Synergistic Deoxynucleoside and Gene Therapies for Thymidine Kinase 2 Deficiency

    Annals of neurology

Lifespan

upin mice1

1 study

  1. AAV-TK2 extends lifespan in mice.

    “AAV9 delivery of human TK2 cDNA to Tk2KI mice efficiently rescued Tk2 activity in all the tissues tested except the kidneys, delayed disease onset, and increased lifespan.”

    Animalsin Tk2KI mice

    Synergistic Deoxynucleoside and Gene Therapies for Thymidine Kinase 2 Deficiency

    Annals of neurology

Latest

Related